secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0000950170-25-039826
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics doses first patient in [212Pb]VMT01 plus nivolumab combo cohort
--------------------------------------------------------------------------------

- First patient dosed with [212Pb]VMT01 at 1.5 mCi in combination with nivolumab (Opdivo) for MC1R+ metastatic melanoma Phase 1/2a trial.
- Earlier monotherapy cohorts showed no dose-limiting toxicities and early signs of anti-tumor activity, presented at SMR October 2024.
- FDA granted Fast Track Designation for [212Pb]VMT01 in unresectable or metastatic melanoma with MC1R expression in September 2024.
- New cohort explores dual mechanism of targeted alpha-particle therapy plus PD-1 blockade to improve patient outcomes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025039826/0000950170-25-039826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025039826/catx-20250317.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-039826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer